Allergy Shots Not Working? 7 Reasons Why (And What to Do Next)

The AAAAI/ACAAI Practice Parameter specifies that the minimum evaluation period before concluding allergy shots are ineffective is one year of adequate maintenance dosing. This is important: the clock starts from when you reach maintenance dose — not from your first injection. If your build-up took 6 months, you need to reach maintenance and then stay there for 12 more months before a fair assessment can be made. During this time, many patients are still building the immune tolerance that will eventually translate to symptom improvement. Declaring failure at month 6 or even 12 from the first injection is almost always premature. If after a verified year of adequate maintenance there is still no clinically meaningful change, then reassessment of allergen selection, dosing, and diagnosis is warranted.

Yes — and this is often the right step if shots aren't working as expected. If your allergy testing was originally limited to skin prick testing alone, requesting a specific IgE blood panel to cross-validate results is reasonable and may identify discordant sensitizations or new triggers not included in your current extract. Component-resolved diagnostics (CRD) can further refine the molecular allergen components driving your immune response. If you've developed new sensitizations during treatment, your allergist can add these allergens to your extract or create a supplemental vial. Discuss your symptom patterns in detail — which seasons are worst, which exposures trigger the most reaction — to help your allergist evaluate whether the current formula matches your real-world triggers.

Missed doses can significantly undermine allergy shot effectiveness, particularly in the build-up phase. The AAAAI/ACAAI guidelines require dose reductions after gaps: gaps of 14-21 days during build-up require a 25% dose reduction; gaps of 21-28 days require 50% reduction; gaps of 90+ days require restarting. Each dose reduction means returning to a lower level of allergen exposure, slowing the accumulation of immune tolerance. In the maintenance phase, gaps of more than 4 weeks also require dose adjustments. Patients who repeatedly miss doses due to travel, illness, or scheduling difficulties may never actually reach or sustain the therapeutic dose needed for efficacy — experiencing the inconvenience of shots without achieving the immunologic benefit. This is exactly where at-home SCIT helps: with Curex you self-inject at home on schedule and dose changes are supervised live over Zoom by the prescribing allergist, so the travel and scheduling friction that drives most gaps is largely removed. Dosing consistency is one of the most impactful things patients can do to maximize the likelihood of success.

Component-resolved diagnostics (CRD) identify the specific molecular proteins within an allergen source that your immune system is reacting to — not just whether you're 'allergic to grass pollen' generally, but which specific grass pollen proteins. This matters for treatment because some allergen components are genuine disease drivers while others are cross-reactive proteins that appear positive on conventional testing without causing real-world symptoms. Matricardi et al. (Allergy, 2016) showed CRD can identify true molecular triggers in cases where conventional testing gives ambiguous or discordant results — up to 30% of patients. For allergy shot patients who aren't responding, CRD can determine whether the current extract contains the right molecular components at adequate levels, or whether the patient's true driver is a component not well-represented in standard commercial extracts.

Not necessarily — two years of treatment with confirmed adequate maintenance dosing warrants a thorough reassessment rather than automatic discontinuation. First, verify the allergen selection using component-resolved diagnostics or updated specific IgE testing. Second, confirm the dose is at the documented therapeutic target for your specific allergens. Third, rule out non-allergic rhinitis components, new sensitizations, or comorbid conditions that may be masking improvement. Fourth, review your appointment records for gaps that may have repeatedly reset your dose. If all these factors have been addressed and there is still no clinical improvement after 18+ months of verified adequate maintenance dosing, then — per the AAAAI/ACAAI Practice Parameter — discontinuation and consideration of alternative approaches is reasonable. Your allergist is the right person to lead this evaluation.

Switching from SCIT to SLIT is a documented consideration for patients who don't respond adequately to injections. SLIT activates immune tolerance through oral mucosal T cells and dendritic cells, while SCIT activates through skin subcutaneous dendritic cells and lymphatics — a different immune geography that may produce a different response in some patients. Case reports and small series suggest some SCIT non-responders respond to SLIT, and vice versa. Before switching, it's important to verify that the reason for SCIT failure isn't a modifiable factor (wrong allergen, inadequate dose, mixed rhinitis) that would affect SLIT equally. If the failure appears to be route-related rather than allergen-selection related, a switch is reasonable to discuss with your allergist.